Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost “Glaucoma and stem cells” has been added to your cart. View cart €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Family studies of primary open-angle glaucoma €15.00 Add to cart Molecular differences in segmental regions of the trabecular meshwork €15.00 Add to cart Dynamic mechanobiology of conventional outflow €15.00 Add to cart Novel surgical methods for addressing glaucoma €15.00 Add to cart